Skip to main content
HEALTHYEATS GUIDE
Disease Prevention and Management

Inluriyo for Breast Cancer: 6 Essential Facts to Know

Inluriyo for breast cancer: who qualifies, how imlunestrant works, the 400 mg daily dose, ESR1 testing, side effects, cost factors and warning signs.

By

Published

Updated

10 min read

Doctor explains Inluriyo for breast cancer treatment options and monitoring.

Introduction

Inluriyo (imlunestrant) is a once-daily pill for a specific type of advanced breast cancer. The FDA approved it on September 25, 2025, for adults with estrogen receptor (ER)-positive, HER2-negative breast cancer that has spread or cannot be removed with surgery, carries a mutation in the ESR1 gene, and has grown despite at least one previous hormone (endocrine) therapy. In September 2026, the FDA expanded the label to include use together with abemaciclib in the same group of patients.

For people whose cancer has stopped responding to standard hormone therapy, a new oral option can matter a great deal. This guide covers six essential facts about Inluriyo, based on the FDA-approved prescribing information and FDA's approval summary: what it is, how it works, how it is taken, side effects, cost factors and who qualifies. It is meant to support, not replace, conversations with your oncology team.

1. What Is Inluriyo and Why Does It Matter for Breast Cancer Treatment?

Woman highlights ESR1 mutation breast cancer awareness with pink ribbon.

Inluriyo is an estrogen receptor antagonist taken by mouth. It is often described as an oral selective estrogen receptor degrader, or SERD, because it both blocks the estrogen receptor and helps the cell break it down.

Understanding hormone receptor-positive breast cancer

About two out of three breast cancers are hormone receptor-positive, meaning estrogen helps them grow. Treatments that lower estrogen or block its receptor are the backbone of care for this type. Knowing the exact type of breast cancer, including its receptor status and mutations, guides the right treatment.

Why endocrine therapy resistance happens

Over time, many advanced cancers stop responding to hormone therapy. One common reason is a mutation in ESR1, the gene that makes the estrogen receptor. These mutations often appear after treatment with aromatase inhibitors and allow the receptor to stay switched on even when estrogen levels are very low.

Who may benefit from Inluriyo?

Inluriyo is designed for cancers with ESR1 mutations. Because it targets the receptor itself rather than estrogen supply, it can still work when the receptor has changed.

FeatureDetails
Active ingredientImlunestrant
Drug typeOral selective estrogen receptor degrader (SERD)
Main useCertain advanced or metastatic breast cancers
TargetEstrogen receptor pathway
Common cancer typeHR-positive, HER2-negative breast cancer

2. How Does Inluriyo Work for Breast Cancer?

Patient asks about Inluriyo dosage during oral SERD treatment consultation.

Inluriyo as an estrogen receptor degrader

Imlunestrant attaches to the estrogen receptor, blocks its activity and marks it for breakdown. With fewer working receptors, cancer cells lose a key growth signal.

Benefits shown in clinical studies

The approval was based on EMBER-3, a randomized trial in people with ER-positive, HER2-negative advanced breast cancer that had progressed after an aromatase inhibitor, with or without a CDK4/6 inhibitor. In the 256 patients with ESR1 mutations, FDA reports that:

  • Median progression-free survival was 5.5 months with Inluriyo versus 3.8 months with the doctor's choice of standard hormone therapy.
  • The risk of the cancer growing or death was reduced by 38% (hazard ratio 0.62).
  • Tumors shrank in 14.3% of people on Inluriyo compared with 7.7% on standard therapy.

Overall survival data were not yet mature at the time of approval.

Oral treatment advantages

The older SERD, fulvestrant, is given as monthly injections into the buttock muscles. Inluriyo is taken at home as tablets, which many people find more convenient.

Treatment TypeHow It WorksAdministration
Aromatase inhibitorsReduce estrogen productionOral tablets
SERMsBlock estrogen receptorsOral tablets
Injectable SERDsDegrade estrogen receptorsInjection
Inluriyo (Imlunestrant)Oral estrogen receptor degradationOral tablet

3. What Is the Inluriyo Dosage and How Is It Taken?

Advocates discuss Inluriyo cost and equitable breast cancer treatment access.

How is Inluriyo taken?

The recommended dose is 400 mg by mouth once a day, taken as two 200 mg tablets, until the cancer progresses or side effects become too difficult. Key instructions from the label:

  • Take it on an empty stomach, at least two hours before food or one hour after food.
  • Take it at about the same time each day.
  • Swallow tablets whole. Do not split, crush or chew them.
  • People with moderate or severe liver impairment are usually given a lower dose of 200 mg once daily.
  • If you miss a dose by six hours or more, or vomit after taking it, skip it and take the next dose at the usual time the following day.

People with moderate or severe liver problems usually take a lower dose of 200 mg daily. Your doctor may also lower the dose if side effects occur.

Monitoring during treatment

Expect regular blood tests for blood counts, liver enzymes and cholesterol and triglyceride levels, plus scans to see how the cancer is responding.

Importance of medical supervision

Inluriyo interacts with some medicines, especially strong CYP3A inhibitors or inducers, which change how much drug reaches the blood. Tell your team about every prescription, over-the-counter medicine and supplement you take, including herbal products such as St. John's wort. Premenopausal and perimenopausal women, and men, typically also receive a medicine that suppresses hormone production from the ovaries or testes.

4. What Are the Side Effects of Inluriyo?

Patient reviews imlunestrant side effects before taking oral SERD treatment.

Common Imlunestrant side effects

In the trial, the most common side effects and lab changes (in at least 10% of people taking Inluriyo alone) included:

  • Musculoskeletal pain
  • Fatigue
  • Diarrhea, nausea, constipation and abdominal pain
  • Lower hemoglobin, neutrophils, platelets and calcium on blood tests
  • Raised liver enzymes (AST and ALT)
  • Higher triglycerides and cholesterol

Serious reactions requiring medical advice

Inluriyo can harm an unborn baby. People who could become pregnant, and men with partners who could, should use effective contraception during treatment and for one week after the last dose, as advised in the label. When Inluriyo is combined with abemaciclib, the label says to follow whichever medicine calls for the longer period after stopping, so ask your care team how long to continue birth control and avoid breastfeeding. Tell your team right away about yellowing of the skin or eyes, dark urine or severe tiredness, which may point to liver problems.

Gentle activity, a regular sleep routine and small, frequent meals can ease fatigue and nausea. Our article on what to eat when you have no appetite has practical ideas. Ask before using any anti-diarrhea medicine or supplement.

5. How Much Does Inluriyo Cost and What Affects Pricing?

Woman checks Inluriyo dosage instructions before taking prescribed medicine.

Factors affecting Inluriyo cost

Inluriyo is a new brand-name cancer drug, so the list price is high. What you actually pay depends on your insurance plan, whether it is covered as a specialty drug, your deductible and coinsurance, and the pharmacy used. Prices change, so check current figures with your insurer and pharmacy rather than relying on online estimates.

Discussing affordability with your care team

Oncology clinics often have financial counselors who can help with prior authorization and appeals. Ask early, before the first fill.

Planning treatment expenses

Options can include manufacturer support programs, independent cancer charities and Medicare Part D assistance programs. Remember to budget for blood tests, scans and visits as well as the medicine. Our guide on how to advocate for yourself offers tips for these conversations.

6. Who Qualifies for Inluriyo Treatment?

Woman monitors symptoms during Inluriyo for breast cancer therapy.

Typical eligibility considerations

Under the current FDA label, Inluriyo, alone or with abemaciclib, is for adults whose breast cancer is:

  • ER-positive and HER2-negative
  • Advanced or metastatic
  • ESR1-mutated, confirmed by an FDA-authorized test
  • Progressing after at least one line of endocrine therapy

Role of ESR1 mutation testing

The ESR1 mutation is detected with a blood-based (liquid biopsy) test. FDA approved the Guardant360 CDx assay as a companion test alongside Inluriyo. Because ESR1 mutations can develop during treatment, testing is often repeated when cancer progresses.

Importance of personalized cancer care

Inluriyo is one of several options for ESR1-mutated disease. Your oncologist will consider prior treatments, other mutations, symptoms and your goals when recommending the next step.

When to See a Doctor

Contact your oncology team promptly if you have:

  • Diarrhea, nausea or vomiting that keeps you from eating or drinking
  • Yellowing skin or eyes, dark urine or pain in the upper right abdomen
  • Fever or chills, which may signal infection when blood counts are low
  • Unusual bruising or bleeding
  • New or worsening bone pain, headaches or shortness of breath

Emergency: Call 911 (or your local emergency number) if you have chest pain, severe trouble breathing, signs of a stroke such as sudden weakness or trouble speaking, heavy bleeding or fainting.

Conclusion

Inluriyo gives people with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer an oral option after hormone therapy stops working. It is taken as 400 mg once daily on an empty stomach, requires an ESR1 blood test to confirm eligibility, and needs regular monitoring for blood count, liver and lipid changes. Working closely with your oncology team, including on cost and side-effect management, helps you get the most from treatment.

Sources

FAQ

1. What is Inluriyo used for?

Inluriyo treats adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed after at least one hormone therapy. It can be used alone or with abemaciclib.

2. When did the FDA approve Inluriyo?

The FDA approved Inluriyo on September 25, 2025. Use in combination with abemaciclib was added to the label in September 2026.

3. How should Inluriyo be taken?

Take 400 mg (two 200 mg tablets) by mouth once daily on an empty stomach, at least two hours before or one hour after food, and swallow the tablets whole.

4. Do I need a test before starting Inluriyo?

Yes. An FDA-authorized blood test must show an ESR1 mutation. The Guardant360 CDx assay was approved as a companion test.

5. What are common side effects of Inluriyo?

Common effects include muscle and joint pain, fatigue, diarrhea, nausea and changes in blood counts, liver enzymes and cholesterol or triglycerides on blood tests.

About the author

Photo of Haider Nadeem

Health Researcher and Writer

Haider Nadeem is a health researcher and the writer behind Healthy Eats Guide. He writes about health problems he faces or sees people around him face, and turns careful research into practical guides. Articles are researched and drafted with AI assistance, then fact-checked and edited by Haider using cited sources such as USDA, NIH, and peer-reviewed research.

More about Haider Nadeem and how articles are made

Related blogs

Skin markings showing 3 types of skin cancer
Disease Prevention and Management

3 Types of Skin Cancer: Essential Facts You Must Know

3 types of skin cancer explained: how basal cell, squamous cell and melanoma look, the ABCDEs, diagnosis, treatment, survival and simple prevention steps.

10 min read

Exhausted woman coping with Mounjaro fatigue and reduced Mounjaro energy levels.
Disease Prevention and Management

Mounjaro Fatigue: 5 Essential Facts to Know

Mounjaro fatigue explained: what the FDA label says, 5 key facts about tirzepatide tiredness, common causes like low intake and dehydration, and when to seek care.

9 min read

Doctor consultation about Depemokimab uses for asthma management
Disease Prevention and Management

Exdensur for Asthma: 7 Essential Facts to Know

Exdensur for asthma explained: how depemokimab works, who qualifies, the twice-yearly dosing schedule, trial results, side effects and its nasal polyp status.

10 min read

Newsletter

Get practical nutrition guides in your inbox

Clear food-by-food advice and diet tips for everyday eating — no spam, unsubscribe anytime.

How often should we email you?

We’ll only email you about nutrition and diet. Unsubscribe anytime. Privacy Policy.